Literature DB >> 11984538

Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C.

Michael J P Arthur.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11984538     DOI： 10.1053/gast.2002.33367

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  73 in total

1.  Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin.

Authors:  María Trapero-Marugán; Jorge Mendoza; María Chaparro; Leticia González-Moreno; José Andrés Moreno-Monteagudo; María Jesús Borque; Ricardo Moreno-Otero
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

Review 2.  Anti-fibrogenic strategies and the regression of fibrosis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

Review 3.  Recent advances in the pathogenesis and diagnosis of liver fibrosis.

Authors:  Natalie J Török
Journal:  J Gastroenterol       Date:  2008-07-01       Impact factor: 7.527

4.  Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice.

Authors:  David J van Westerloo; Sandrine Florquin; Anita M de Boer; Joost Daalhuisen; Alex F de Vos; Marco J Bruno; Tom van der Poll
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

5.  Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients.

Authors:  Sarah L George; Bruce R Bacon; Elizabeth M Brunt; Kusal L Mihindukulasuriya; Joyce Hoffmann; Adrian M Di Bisceglie
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

Review 6.  Putting it all together: established and emerging MRI techniques for detecting and measuring liver fibrosis.

Authors:  Suraj D Serai; Andrew T Trout; Alexander Miethke; Eric Diaz; Stavra A Xanthakos; Jonathan R Dillman
Journal:  Pediatr Radiol       Date:  2018-08-04

7.  Comprehensive characterization of serum clinical chemistry parameters and the identification of urinary superoxide dismutase in a carbon tetrachloride-induced model of hepatic fibrosis in the female Hanover Wistar rat.

Authors:  Rosemary Smyth; Michael R Munday; Malcolm J York; Christopher J Clarke; Theo Dare; John A Turton
Journal:  Int J Exp Pathol       Date:  2007-10       Impact factor: 1.925

8.  Inhibition of connective tissue growth factor suppresses hepatic stellate cell activation in vitro and prevents liver fibrosis in vivo.

Authors:  Chunqiu Hao; Yumei Xie; Meijuan Peng; Li Ma; Yun Zhou; Yan Zhang; Wenzhen Kang; Jiuping Wang; Xuefan Bai; Pingzhong Wang; Zhansheng Jia
Journal:  Clin Exp Med       Date:  2013-03-02       Impact factor: 3.984

Review 9.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

Review 10.  Pathogenesis of liver cirrhosis.

Authors:  Wen-Ce Zhou; Quan-Bao Zhang; Liang Qiao
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.